Case Report

J Rheum Dis 2016; 23(3): 187-192

Published online June 30, 2016

© Korean College of Rheumatology

A Case of Sarcoidosis That Improved upon Discontinuation of Etanercept

Ji-Hyoun Kang, Joon-Ho Ahn, Ji-Eun Yu, Ji-Eun Kim, Yi-Rang Yim, Jeong-Won Lee, Kyung-Eun Lee, Dong-Jin Park, Lihui Wen, Yong-Wook Park, Shin-Seok Lee

Division of Rheumatology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea

Correspondence to : Shin-Seok Lee, Division of Rheumatology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, 42 Jebong-ro, Dong-gu, Gwangju 61469, Korea. E-mail:shinseok@chonnam.ac.kr

Received: July 2, 2015; Revised: August 22, 2015; Accepted: August 24, 2015

This is a Free Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

A 31-year-old man who had been prescribed etanercept over a 3-year period for treatment of ankylosing spondylitis presented with newly developed dry cough, chills, myalgia, and weight loss. Chest computed tomography showed multiple reticulonodular pulmonary infiltrates and bilateral mediastinal, hilar, and peribronchial lymphadenopathy. Biopsy of a paratracheal lymph node revealed chronic granulomatous inflammation without necrosis, and the serum angiotensin-converting enzyme level was elevated. Sarcoidosis was diagnosed. His laboratory and radiological findings, and clinical symptoms improved only after discontinuation of etanercept without treatment. Although etanercept-induced sarcoidosis is rare, this case report suggests that sarcoidosis should be considered in the differential diagnosis of patients treated with the tumor necrosis factor inhibitor. (J Rheum Dis 2016;23:187-192)

Keywords Etanercept, Sarcoidosis, Ankylosing spondylitis

Article

Case Report

J Rheum Dis 2016; 23(3): 187-192

Published online June 30, 2016

Copyright © Korean College of Rheumatology.

A Case of Sarcoidosis That Improved upon Discontinuation of Etanercept

Ji-Hyoun Kang, Joon-Ho Ahn, Ji-Eun Yu, Ji-Eun Kim, Yi-Rang Yim, Jeong-Won Lee, Kyung-Eun Lee, Dong-Jin Park, Lihui Wen, Yong-Wook Park, Shin-Seok Lee

Division of Rheumatology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea

Correspondence to:Shin-Seok Lee, Division of Rheumatology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, 42 Jebong-ro, Dong-gu, Gwangju 61469, Korea. E-mail:shinseok@chonnam.ac.kr

Received: July 2, 2015; Revised: August 22, 2015; Accepted: August 24, 2015

This is a Free Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

A 31-year-old man who had been prescribed etanercept over a 3-year period for treatment of ankylosing spondylitis presented with newly developed dry cough, chills, myalgia, and weight loss. Chest computed tomography showed multiple reticulonodular pulmonary infiltrates and bilateral mediastinal, hilar, and peribronchial lymphadenopathy. Biopsy of a paratracheal lymph node revealed chronic granulomatous inflammation without necrosis, and the serum angiotensin-converting enzyme level was elevated. Sarcoidosis was diagnosed. His laboratory and radiological findings, and clinical symptoms improved only after discontinuation of etanercept without treatment. Although etanercept-induced sarcoidosis is rare, this case report suggests that sarcoidosis should be considered in the differential diagnosis of patients treated with the tumor necrosis factor inhibitor. (J Rheum Dis 2016;23:187-192)

Keywords: Etanercept, Sarcoidosis, Ankylosing spondylitis

JRD
Oct 01, 2024 Vol.31 No.4, pp. 191~263
COVER PICTURE
Ancestry-driven pathways for SLE-risk SNP-associated genes. The ancestry-driven key signaling pathways in Asians, Europeans, and African Americans were analyzed by enrichr (https://maayanlab.cloud/Enrichr/#libraries) using non-HLA SNP-associated genes. SLE: systemic lupus erythematosus, SNP: single-nucleotide polymorphism, JAK–STAT: janus kinase–signal transducers and activators of transcription, IFN: interferon gamma. (J Rheum Dis 2024;31:200-211)

Stats or Metrics

Share this article on

  • line

Related articles in JRD

Journal of Rheumatic Diseases

pISSN 2093-940X
eISSN 2233-4718
qr-code Download